Vystar Q3 10-Q: Going Concern Doubt, $65,784 Cash, Material Weaknesses
VYST has more than doubled off its 52-week low of $0.017.
Summary
Vystar's Q3 2026 10-Q reiterates substantial doubt about its ability to continue as a going concern, with $65,784 of cash and a ~$7.2 million working capital deficit, while disclosing ineffective internal controls and a $91,532 quarterly net loss.
Key Events · Earnings and Guidance · VYST
-
Going Concern Doubt Reiterated
At September 30, 2026 the company had $65,784 of cash, a working capital deficit of about $7.2 million and an accumulated deficit of about $62.1 million; management says it may need to file bankruptcy or cease operations absent new financing.
-
Q3 Revenue Up on One-Time Sale
Revenue was $60,840 versus $20,385 a year earlier, an increase of $40,455 or 198.5%, driven mainly by a bulk Vytex sale of approximately $54,000; net loss narrowed to $91,532 from $271,387.
-
Internal Controls Deemed Ineffective
Management concluded internal control over financial reporting was not effective as of September 30, 2026, citing insufficient segregation of duties, no formal CFO, no functioning audit committee and weak controls over embedded debt features.
-
r3alm JV Adds Equity True-Up
Vystar acquired 50% of r3alm, Inc. on August 4, 2026 for $50,000 cash, 8,371 Series B preferred shares and a $200,000 deferred payment, and guaranteed Capital Realm a 34% common ownership position with a two-year true-up.
Analysis · VYST · Manufacturing
The going-concern warning remains front and center in Vystar's quarterly report: $65,784 of cash against a working capital deficit of roughly $7.2 million and a $62.1 million accumulated deficit. Management says it may have to file bankruptcy or cease operations if it cannot raise equity or debt and grow RxAir and Vytex revenue. Revenue rose to $60,840 from $20,385 a year earlier, but the gain came mostly from a one-time ~$54,000 bulk Vytex sale, and the quarter still lost $91,532. Internal control over financial reporting was also disclosed as not effective, citing insufficient segregation of duties, no formal CFO, no functioning audit committee, and weak controls over embedded debt features. The r3alm joint venture adds a 34% common-equity guarantee with a two-year true-up that could require more share issuance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VYST was trading at $0.06 on OTC in the Manufacturing sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.02 to $0.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.